Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.73 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.73 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.60 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.60 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31335790 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1PDK1 | |
| SCHEMBL4143307 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1HSP90B1TRAP1PDK1 | |
| SCHEMBL4150717 | 0.84 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4145940 | 0.84 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4156177 | 0.84 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4144014 | 0.83 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4159256 | 0.82 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4151241 | 0.80 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4151310 | 0.80 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL384744 | 0.78 | HSP90AA1 (0.82) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | claimed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | claimed |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-15 | — | — | US | claimed |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | US | claimed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | claimed |
| EP-2073802-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073804-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073803-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| EP-2073807-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | claimed |
| CN-101193862-A | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2008-06-04 | — | — | CN | claimed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | claimed |
| EP-1879863-A1 | AMIDE RESORCINOL COMPOUNDS | Pfizer, Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | claimed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | claimed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| US-10167258-B2 | Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-01 | — | — | US | disclosed |
| US-10167258-B2 | Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-01 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2073804-B1 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ASTEX THERAPEUTICS LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20170001958-A1 | INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001958-A1 | INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001958-A1 | INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015089360-A1 | INHIBITORS OF MITOCHNONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2015-02-12 | — | — | US | disclosed |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2015-02-12 | — | — | US | disclosed |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8916552-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8916552-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8916552-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| EP-2332909-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2332909-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8816087-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-8816087-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-8816087-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-8779132-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8779132-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8779132-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8530469-B2 | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530469-B2 | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530469-B2 | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2013-09-10 | — | — | US | disclosed |
| CN-101193862-B | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD | 2013-08-21 | — | — | CN | disclosed |
| EP-1877379-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-1877379-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8101648-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-24 | — | — | US | disclosed |
| US-8101648-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-24 | — | — | US | disclosed |
| US-8101648-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-24 | — | — | US | disclosed |
| EP-2332909-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | Astex Therapeutics Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332909-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | Astex Therapeutics Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100216782-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | CHESSARI GIANNI | 2010-08-26 | — | — | US | disclosed |
| US-20100216782-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | CHESSARI GIANNI | 2010-08-26 | — | — | US | disclosed |
| US-20100216782-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | CHESSARI GIANNI | 2010-08-26 | — | — | US | disclosed |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-20100152184-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152184-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152184-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-7700625-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LTD. (GB) | 2010-04-20 | — | — | US | disclosed |
| US-7700625-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LTD. (GB) | 2010-04-20 | — | — | US | disclosed |
| US-7700625-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LTD. (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090215772-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LIMITED (UK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215772-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LIMITED (UK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215772-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LIMITED (UK) | 2009-08-27 | — | — | US | disclosed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-2081891-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-2073802-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-2073804-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-2073803-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-2073807-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| CN-101193862-A | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2008-06-04 | — | — | CN | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044027-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044027-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044054-A2 | HYDROXY-SUBSTITUTED BENZOIC ACID AMIDE COMPOUNDS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-1879863-A1 | AMIDE RESORCINOL COMPOUNDS | Pfizer, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | HSP90AA1 1/4885HSP90AB1 2/4885HSP90B1 12/4885 |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 5/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | HSP90AA1 2/4885HSP90AB1 3/4885HSP90B1 11/4885 |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | HSP90AB1, HEATR6, HEATR1 | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 7/4885 |
| US-20100216782-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 5/4885 |
| US-20170001958-A1 | INHIBITORS OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE KINASE ISOFORMS 1-4 AND USES THEREOF | PDK4, PDK2, PDK3 | HSP90AA1 26/4885HSP90AB1 19/4885HSP90B1 30/4885 |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 4/4885 |
| US-20100152184-A1 | PHARMACEUTICAL COMPOUNDS | RPP30, RPLP1, NR5A1 | HSP90AA1 7/4885HSP90AB1 4/4885HSP90B1 33/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 5/4885 |
| US-20090215772-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 5/4885 |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 5/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | HSP90AA1 105/4885HSP90AB1 49/4885HSP90B1 86/4885 |
| US-10167258-B2 | Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof | PDK4, PDK2, PDK3 | HSP90AA1 26/4885HSP90AB1 19/4885HSP90B1 30/4885 |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | H1-10, C1R, C1S | HSP90AA1 3726/4885HSP90AB1 4036/4885HSP90B1 3671/4885 |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, CDK6 | HSP90AA1 68/4885HSP90AB1 23/4885HSP90B1 63/4885 |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.